title: Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4).
authors.affiliation: Queen's University, Kingston, Canada.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Morales
authors.affiliation: MD Anderson Cancer Center, Houston, Texas.
authors.forename: Ashish
authors.initials: A
authors.lastname: Kamat
authors.affiliation: University of Chicago Medical Center, Chicago, Illinois.
authors.forename: Gary
authors.initials: G
authors.lastname: Steinberg
authors.affiliation: Urology of Virginia, Virginia Beach, Virginia.
authors.forename: Robert
authors.initials: R
authors.lastname: Given
authors.affiliation: McDougall Scientific, Toronto, Canada.
authors.forename: John
authors.initials: J
authors.lastname: Amrhein
authors.affiliation: Telesta Therapeutics, Pointe-Claire, QC, Canada.
authors.forename: Zvi
authors.initials: Z
authors.lastname: Cohen
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Harry
authors.initials: H
authors.lastname: Herr
mesh_terms: D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D006801:Humans; D011446:Prospective Studies; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D001500:BCG Vaccine